Evidence map›Paper›PMID 39963829›Full record

ArticleThe oncologist2025

Differentiating between renal medullary and clear cell renal carcinoma with a machine learning radiomics approach.

Rahim Jiwani, Koustav Pal, Iwan Paolucci, Bruno Odisio, Kristy Brock, Nizar M Tannir, Daniel D Shapiro, Pavlos Msaouel, Rahul A Sheth

Abstract read
In one paragraph

Article in The oncologist, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Renal Medullary Carcinoma: Utility of [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Rahim JiwaniDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Koustav PalDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0002-0777-2260
Iwan PaolucciDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0002-9393-3015
Bruno OdisioDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Kristy BrockDepartment of Imaging Physics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Nizar M TannirDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.
Daniel D ShapiroDepartment of Urology, University of Wisconsin School of Medicine and Public Health, Madison, WI 77030, United States.
Pavlos MsaouelDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.ORCID 0000-0001-6505-8308
Rahul A ShethDepartment of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, United States.

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
Mechanisms of Hyperprogression to Immunotherapy in SMARCB1-Deficient Renal MalignanciesR37CA288448 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Pavlos Msaouel · 2024 to 2026
$2.0M
An image-guided immunotherapy and hyperthermia delivery device to overcome barriers to tumor immunity for advanced hepatocellular carcinomaR37CA269622 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Rahul Anil Sheth · 2023 to 2026
$1.8M
Advanced Discovery AwardAndrew Sabin Family Foundation FellowshipGateway for Cancer ResearchImage Guided Cancer Therapy Research ProgramJohnson FoundationKidney Cancer AssociationMD Anderson Physician-Scientist AwardMD Anderson's PrometheusNCI NIH HHS P30 CA016672NCI NIH HHS R37 CA269622NCI NIH HHS R37CA269622NCI NIH HHS R37 CA288448NCI NIH HHS R37CA288448Translational Research AwardTranslational Research Partnership Award KC200096P1United States Department of DefenseV Foundation
6 · The paper itself

Abstract

backgroundThe objective of this study was to develop and validate a radiomics-based machine learning (ML) model to differentiate between renal medullary carcinoma (RMC) and clear cell renal carcinoma (ccRCC).

methodsThis retrospective Institutional Review Board -approved study analyzed CT images and clinical data from patients with RMC (n = 87) and ccRCC (n = 93). Patients without contrast-enhanced CT scans obtained before nephrectomy were excluded. A standard volumetric software package (MIM 7.1.4, MIM Software Inc.) was used for contouring, after which 949 radiomics features were extracted with PyRadiomics 3.1.0. Radiomics analysis was then performed with RadAR for differential radiomics analysis. ML was then performed with extreme gradient boosting (XGBoost 2.0.3) to differentiate between RMC and ccRCC. Three separate ML models were created to differentiate between ccRCC and RMC. These models were based on clinical demographics, radiomics, and radiomics incorporating hemoglobin electrophoresis for sickle cell trait, respectively.

resultsPerformance metrics for the 3 developed ML models were as follows: demographic factors only (AUC = 0.777), calibrated radiomics (AUC = 0.915), and calibrated radiomics with sickle cell trait incorporated (AUC = 1.0). The top 4 ranked features from differential radiomic analysis, ranked by their importance, were run entropy (preprocessing filter = original, AUC = 0.67), dependence entropy (preprocessing filter = wavelet, AUC = 0.67), zone entropy (preprocessing filter = original, AUC = 0.67), and dependence entropy (preprocessing filter = original, AUC = 0.66).

conclusionA radiomics-based machine learning model effectively differentiates between ccRCC and RMC. This tool can facilitate the radiologist's ability to suspicion and decrease the misdiagnosis rate of RMC.

Indexed as

Carcinoma, MedullaryCarcinoma, Renal CellKidney MedullaKidney NeoplasmsMachine LearningAdultAgedDiagnosis, DifferentialFemaleHumansMaleMiddle AgedRadiomicsRetrospective StudiesTomography, X-Ray Computedclear cell renal carcinomaradiomicsrenal medullary carcinoma

Identifiers

PMID39963829
PMCPMC11833245

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.